Replies to post #262246 on Avid Bioservices Inc (CDMO)

[Carboat]

A) The PPHM share price is undervalued and does not reflect the value of the underlying assets (otherwise selling IP/Pipelines will change NOTHING to the PPS and they can as well keep them because everyone that would want out can do it at the current price because the sell out will do noting for the PPS).

No. Breakup value is often more than the sum of the parts. Inherent in the breakup is the stopping of expenses/burn and the capture of cash before dilution.

It says that you do not believe that the current BoD/Management can realize that value (that is where we differ in opinion, although at this point not longer ALONE but with a strong partner due to the difference in nature between economics of chemo and I-O combo clinical trials). Every OTHER small cap biotech would have been death if it had to go through what PPHM went through the past decade. But PPHM has cash, no creditors and owns it's IP/Pipelines unencumbered and has a lucrative Avid production facility. That is also BoD/Management's doing.

All they have done is spend mucho $$ and erode shareholder value. Sunrise was a total waste as was the PII by association. At $.40 they can surely be fairly described as near-death now.

Finally it shows disbelief in what world class collaborators parties believe. They extend their collaborations with PPHM/Bavituximab based on observations of a first series of tests that where done. I think Memorial Sloan Kettering, NCCN and AstraZeneca's involvement in the Bavituximab path set-out will reflect where the future lies.

Scientists explore all sorts of things. Some work out, some do not. And NCCN is a for-hire group, the bar is pretty low there.

[geocappy1]

IMO they need to partner it in a big way or sell it. Partner in a way (regardless of up front money), that guarantees the partner has to aggressively develop the IP. Then, get rid of all the crony BOD members who add nothing to the board but a vote for ES when he wants it.

[revenue_monster]

Volume was rather light after the PR when compared to outstanding shares

[corporalagarn]

"Every OTHER small cap biotech would have been death if it had to go through what PPHM went through the past decade."

Actually, every other small cap biotech with decent management and something valuable would have partnered long ago and be worth a large multiple of what we are currently trading at. That is pretty plain to see. To say that a management team that has lost over 95% of shareholder value did not screw up is just being disingenuous at best, purposefully misleading, for some reason, at worst.